Medication Monitor

Generic Name (Trade Name—Company)
May 31, 2011


(Various oral contraceptives—Various manufacturers)
VT risks increased

A safety communication released by FDA highlighted data from two recently published studies that reported a two- to three-fold greater risk of venous thromboembolic events in women taking oral contraceptives containing drospirenone as compared with those taking contraceptive therapy containing levonorgestrel. FDA noted that previous data have had conflicting results, with other studies not reporting any difference in the venous thromboembolic risk between drospirenone-containing products and products containing levonorgestrel or other progestins. The agency is reviewing these and other data and will communicate any new safety information as it becomes available.